Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 13/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981528 | 1.00 | METAP2 (0.46) | METAP2SNCAACLYLMNASMN1; SMN2 | |
| SCHEMBL4251300 | 0.93 | METAP2 (0.54) | METAP2SNCASLC16A3 | |
| SCHEMBL4251296 | 0.93 | METAP2 (0.54) | METAP2SNCASLC16A3 | |
| SCHEMBL3981384 | 0.81 | METAP2 (0.50) | METAP2ACLYSLC16A3 | |
| SCHEMBL3986601 | 0.78 | METAP2 (0.53) | METAP2SMN1; SMN2 | |
| SCHEMBL3988657 | 0.78 | METAP2 (0.56) | METAP2ACLYLMNA | |
| SCHEMBL3979854 | 0.75 | METAP2 (0.56) | METAP2ACLYSMN1; SMN2SLC16A3 | |
| SCHEMBL3982084 | 0.74 | METAP2 (0.59) | METAP2ACLYSLC16A3 | |
| SCHEMBL3985586 | 0.71 | METAP2 (0.44) | METAP2 | |
| SCHEMBL3985573 | 0.71 | METAP2 (0.44) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885SNCA 4788/4885ACLY 2986/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885SNCA 4788/4885ACLY 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.